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Abstract
Background: As ovarian cancer stem cells (CSCs) are responsible for tumor initiation, invasion, metastasis, and
chemo-resistance, new stratagems that selectively target ovarian CSCs are critically significant. Our previous work
have demonstrated that ovarian cancer spheroid cells are tumorigenic and chemo-resistant, and have the
properties of ovarian CSCs. Herein, we hypothesized that expressing α-gal epitopes on ovarian spheroid cells may
help eliminate CSCs and improve the outcome of therapeutic intervention for ovarian cancer patients.
Methods: Lentivirus-mediated transfer of a pig α(1,3)galactosyltransferase [α1,3GT] enzyme gene into human
ovarian cell line SKOV3 cells formed α-gal epitope-expressing cells (SKOV3-gal cells), and then these cells were
maintained in a serum-free culture system to form SKOV3-gal spheroid cells. Efficacy of this cell vaccine was
demonstrated in α1,3GT knockout mice (α1,3GT KO mice).
Results: The antibody titers to α-gal epitopes measured by ELISA were significantly increased in α1,3GT KO mice
after immunization with SKOV3-gal spheroid cells. Furthermore, compared with the non-immunized KO mice, the
SKOV3 tumors grafted under renal capsules of KO mice immunized with SKOV3-gal spheroid cells grew slower and
began to shrink on day 12. Western blot analysis also showed that immunized KO mice can produce effective
antibody against certain tumor associated antigens (TAAs) derived from both SKOV3 cells and SKOV3 spheroid cells.
The TAAs were further investigated by mass spectrometry and RNA interference (RNAi) technology. The results
suggested that antibodies responding to protein c-erbB-2 may be raised in the sera of the mice after immunization
with SKOV3-gal spheroid cells. Ultimately, vaccination with SKOV3-gal spheroid cells induced more CD3 + CD4 + T
cells in the spleen of immunized mice than non-immunized KO mice.
Conclusions: The results suggest that vaccination using ovarian cancer stem-like cells engineered to express α-gal
epitopes may be a novel strategy for treatment of ovarian cancer.
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Background
Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy. Most ovarian cancer patients
are treated with cytoreductive surgery followed by com-
bination chemotherapy. Although the majority of pa-
tients respond to first-line treatment, most will relapse
and overall survival rates for patients with advanced
EOC remain disappointing [1–3]. As such, it remains
critical to develop an effective therapy to reduce the re-
lapse and achieve long-term remissions.
In recent years, the study of cancer stem cells (CSCs)
has resulted in an improved understanding of carcino-
genesis. CSCs are proposed to represent the fundamen-
tal driving force of tumor development, initiation,
invasion, and metastasis, as well as recurrence [4]. Con-
ventional anti-cancer treatments (e.g. chemotherapy and
radiation) can often transiently shrink tumors, but these
therapies fail to target and kill CSCs, leading to relapse,
and ultimately death [5]. As such, it is necessary to de-
velop an effective stratagem targeting CSCs. Evidence to
date has demonstrated that ovarian CSCs are tumori-
genic and chemo-resistant. Elimination of ovarian CSCs,
therefore, might help improve the sensitivity of chemo-
therapy drugs and reduce the tumor relapse [6, 7].
Considering that the immune system plays a pivotal
role in tumorigenesis, immunotherapy has been estab-
lished as an important component of many cancer treat-
ment regimens, which could destroy cancer cells both in
situ and within the metastatic compartment [8–10]. In
addition, immunotherapy using antibodies (Abs) target-
ing tumor-specific antigens expressed on CSCs can se-
lectively kill CSCs, while sparing the normal counterpart
[11]. Furthermore, tumor vaccines have also showed
promising preliminary data in targeting CSCs. The pre-
requisite for the induction of an effective antitumor im-
mune response by tumor vaccine is the effective uptake
of this vaccine by professional antigen-presenting cells
(APC). It was reported that the addition of α-gal epitope
to MUC1+ pancreatic carcinoma whole-cell vaccine
could enhance presentation to APC and induce immune
responses against not only differentiated cancer cells but
also CSCs [12].
The α-gal epitope is a glycoconjugate present on
cell membranes of non-primate mammals, prosimians
and New World monkeys, but not in humans. How-
ever, the corresponding human anti-Gal antibody was
found to be present in high titer in the serum of
every normal individual studied [13] and is continu-
ously produced as an immunological response to anti-
genic stimulation by bacteria of the normal flora [14].
It is reported that α-gal epitope specific IgG, IgM,
IgD, and IgA titers remained unvaried over longer
time periods in healthy subjects [15]. Tumor cells
engineered to express α-gal epitopes were able to
bind anti-Gal and to be destroyed by this antibody in
an experimental animal model [16].
Consistent with other studies [6, 7], our previous work
demonstrated that ovarian epithelial cancer cells cul-
tured in serum-free medium could form spheroid cells,
which are cancer stem-like cells that have the
characterization of CSCs and can be distinguished from
differentiated ovarian cancer cells [17–19]. Herein, we
hypothesized that biosynthesis of α-gal epitopes to ovar-
ian cancer spheroid cells could effectively induce Abs
production against ovarian cancer stem-like cells.
Using α1,3GT knockout mice, we further investigated
the immune response induced by vaccines expressing
α-gal epitopes against both differentiated ovarian can-
cer cells and cancer stem-like cells.
Methods
Cell culture
All cell lines were obtained from Shanghai Cell Bank of
Chinese Academy of Sciences (Shanghai, China). 293 T
cells (Immortalized human embryonic kidney cells) were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Grand Island, NY) supplemented with
10 % fetal bovine serum (FBS) in a humidified incubator
with 5 CO2 and 95 % air at 37 °C. Human ovarian cancer
cell line SKOV3 cells were maintained in McCoy’s 5A
medium (Sigma-Aldrich, Oakville, ON, Canada) supple-
mented with 10 % FBS. Then the SKOV3 cells were dis-
sociated by 0.02 % trypsin-EDTA and maintained under
stem cell conditions as described before [17–19]. In this
condition, cancer cells grow as non-adherent spheroid
cells. Culture media were changed every 2 days by cen-
trifuging at 800 rpm for 5 min to remove the dead cell
debris. Regular culture plates were coated with poly (2-
hydroxyethyl methacrylate) (Sigma) before spheroid cell
culturing [17–19]. 293 T cells were used for recombinant
lentivirus transfection, amplification, and titration.
Construction of recombinant lentivirus vector expressing
pig α1,3GT gene
Primers for amplification of α1,3GT coding sequence
(α1,3GT CDS) were previously reported by Yu et al.
[20]. Compared with the plasmid profile of pCDH-
CMV-MCS-EF1-copGFP (System Biosciences, Mountain
View, CA), the amplified sequence of α1,3GT CDS was
analyzed for XbaI and BamHI restriction enzymes sites,
and confirmed with NEBcutter V2.0. XbaI and BamHI
restriction sites were designed into the primers of
α1,3GT CDS prior to gene amplification. Both α1,3GT
CDS and pCDH-CMV-MCS-EF1-copGFP was digested
by XbaI and BamHI and the resulting 1.19 kb fragment
of porcine α1,3GT cDNA was subcloned into pCDH-
CMV-MCS-EF1-copGFP to construct pCDH-CMV-
α1,3GT-EF1-copGFP. Finally the recombinant plasmid
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was used to produce lentivirus-based vector with three
plasmid packaging systems including another two plas-
mids - pCMV dR8.91 and VSVG [21]. All three plasmids
were co-transfected into packaging 293 T cells using the
calcium phosphate method [21]. High titers of recom-
binant lentivirus were amplified, purified, and stored.
Eventually SKOV3 cells were transfected with lentivirus
vector at multiplicity of infection (MOI) of 40, which
formed SKOV3-gal cells expressing α-gal epitopes.
Real-time quantitative PCR
After total RNA was isolated from the samples, five hun-
dred nanograms of total RNA from each sample were
reverse transcribed using the primescript RT reagent kit
(Takara Bio Inc., Shiga, Japan). Real-time PCR was per-
formed on cDNA using SYBR Premix Ex Taq (Takara)
on the Mastercycler® ep realplex (Eppendorf, Hamburg,
Germany). All reactions were carried out in triplicate
using a 25-μl volume. In brief, PCR amplification was
carried out using an initial denaturation at 95 °C for
5 min, followed by 40 cycles for 30 s at 95 °C, 30 s at
60 °C, and 30 s at 72 °C. A sample lacking template
DNA was used as a negative control. The primers for
the genes are provided in Additional file 1: Table S1.
Proliferation and drug resistance assessment
SKOV3 cells and SKOV3-gal cells were seeded at a
density of 3 × 103 cells per well in 96-well plates. The
MTT assay was employed to count the viable number of
cells at 1, 2, 3, 4, 5, and 6 days after seeding cells. A
growth curve was plotted for each cell line depicting the
viable number of cells versus the duration post infection.
To assess the effect of α-gal epitopes on drug resist-
ance, SKOV3 cells and SKOV3-gal cells were plated in
culture medium containing cisplatin (Sigma-Aldrich,
20 μmol) for 24 h and 48 h. Cultures were set up in trip-
licate. The proliferation conditions were determined by
MTT assay with an OD reading at 490 nm. Each experi-
ment was repeated three times under the same experi-
mental conditions.
Complement-mediated cell death
Both SKOV3 cells and SKOV3-gal cells were incubated
in the presence of 1:3, 1:6, 1:9, and 1:18 human serum
solution diluted with McCoy’s 5A medium without FBS
for twenty-four hours. Human blood samples were col-
lected from three ovarian cancer patients who were cate-
gorized as stage III, grade 2–3 serous adenocarcinoma
according to the International Federation of Gynecology
and Obstetrics (FIGO) classification. The present study
was approved by the institutional review boards at
Shanghai Jiaotong University and written informed con-
sent was obtained from these patients. SKOV3 cells and
SKOV3-gal cells without human serum and FBS were
used as negative controls. McCoy’s 5A medium without
FBS was used as blank control. Cultures were set up in
triplicate. Proliferation was monitored by MTT assay
under optical density (OD) reading at 490 nm. The per-
centage of survival rate was determined as follows:
(OD490(sample)- OD490(blank control))/(OD490(negative control)-
OD490(blank control)) × 100 %.
Antibody-dependent cell-mediated cytotoxicity (ADCC)
assay
The ADCC assay was performed as described by Tanemura
et al. [22] with minor modifications. SKOV3 cells and
SKOV3-gal cells were plated in 96-well plates. Subse-
quently, peripheral blood mononuclear cells (PBMC) were
obtained by Ficoll–Hypaque centrifugation of venous blood
from ovarian patients and were added to the wells at cell
ratios of 1:20 (effector cells: target cells) in the presence or
absence of serum from the same patient. The plates were
incubated at 37 °C for 72 h and MTT assay was employed
to count the number of viable cells. The percentage of cyto-
toxicity rate was determined as follows: 1-(OD490(sample)-
OD490(PBMC))/OD490(target cells).
Tumor cell vaccination
Six α1,3GT knockout mice were obtained from Dr Jung-
Ah, Cho (Center for animal resource development,
College of Medicine, Seoul National University, Seoul,
Korea). The genotypes were confirmed by polymerase
chain reaction (PCR) on DNA extracted from the tail of
the α1,3GT KO mice [23], with the wild-type (WT) mice
counterpart (C57BL/6) as control. The mice were mated
to supply enough mice for the experiment. Prior to the
experimental procedure, six-week-old KO mice received
4-weekly intraperitoneal immunization of 100 mg of pig
kidney membrane homogenate to induce high titers of
anti-Gal Abs as described previously in humans [22, 24].
Subsequently, the KO mice were vaccinated subcutane-
ously three times at 1 week intervals with 1 × 106
50 Gy–irradiated SKOV3 cells, SKOV3 spheroid cells,
SKOV3-gal cells, or SKOV3-gal spheroid cells. One
week after vaccination, the mice were assessed for the
immune response as described below. All animal proce-
dures were approved by the Institutional Animal Care
and Use Committee of Shanghai, and were performed in
accordance with the National Research Council Guide
for Care and Use of Laboratory.
Enzyme-linked immunosorbent assay (ELISA)
The production of anti-Gal IgG antibody was measured
by ELISA. Galalph1-3Gal beta1-4GlcNAc-BSA (Dextra
Laboratories, Reading, UK) was attached to microtiter
plates at a concentration of 10 μg/ml in carbonate buffer,
pH 9.5. The plates were coated at 4 °C overnight. After
washing five times, 1 % bovine serum albumin in
Yao et al. BMC Cancer  (2015) 15:956 Page 3 of 15
carbonate buffer was added to the wells to prevent non-
specific binding. The serum samples obtained from
vaccinated-KO mice were added at various dilutions
with PBS containing 0.3 % BSA. One hour later, horse-
radish peroxidase (HRP)-linked goat anti-mouse IgG
was added. A color reaction was obtained with peroxid-
ase reagent 3.30, 5.50-tetramethylbenzidine (TMB,
Sigma-Aldrich), and stopped by the addition of 2 M
H2SO4. The optical density was read at 450 nm using a
Bio-Rad ELISA reader.
In vivo studies of tumor cell vaccine in an experimental
mouse model
5 × 106 SKOV3 cells were injected subcutaneously into 6
to 8 week-old female (n = 8) athymic nude mice to form
SKOV3 tumors. After injection, the nude mice were kept
in a specific pathogen-free environment and checked for
tumor development every two days for 1 month. Simul-
taneously, the α1,3GT KO mice were pre-immunized
with pig kidney fragments and then vaccinated with
50 Gy–irradiated SKOV3 cells, SKOV3 spheroid cells,
SKOV3-gal cells, or SKOV3-gal spheroid cells as de-
scribed above. One week after the last immunization,
the tumors formed in nude mice were collected and
stored at 4 °C in Hanks’ balanced salt solution supple-
mented with antibiotics. Within 2 h, the tumor sample
was cut into two parts. One part was fixed for histo-
logical analysis and the other was cut into multiple
1 mm3 pieces, which were meticulously implanted under
the renal capsule of the left kidney (2 grafts per kidney)
of the immunized α1,3GT KO mice (n = 15 in each
group) as described previously by Lee et al. [25]. Subse-
quently, on days 4, 8, and 12 after grafting, five mice in
each group were euthanized under anesthesia and the
kidneys were removed and the grafts were measured in
situ by using a stereoscopic microscope, fitted with an
ocular micrometer, and calibrated in ocular units (OMU,
1OOMU= 1 mm) to examine tumor growth. Two per-
pendicular diameters were measured and the difference
in mean tumor diameter was calculated [26].
Western blotting analysis
The production of Abs toward tumor antigens on SKOV3
cells or SKOV3 spheroid cells was examined by Western
blot analysis using vaccinated KO mice sera. The total
amount of proteins from the cultured cells was subjected
to 10 % SDS-PAGE (50 μg protein each lane) and trans-
ferred onto Hybrid-PVDF membranes (Millipore, Bedford,
USA). After blocking with 10 % (w/v) non-fat dried milk
in TBST (Tris-buffered saline containing Tween-20), the
PVDF membranes were washed with TBST at room
temperature and incubated with immunized α1,3GT KO
mice sera diluted with 5 % (w/v) non-fat dried milk in
TBST overnight. Following extensive washing, membranes
were incubated with HRP-conjugated goat anti-mouse
IgG secondary anti-body (1:5000; Santa Cruz Technology,
Santa Cruz, USA). After washing, the immunoreactivity
was visualized by enhanced chemiluminescence using
ECL kit from Thermo Fisher Scientific.
To confirm whether c-erbB2 protein was existent in
the 185 kDa band and 150 kDa band of the lysates of
SKOV3 adherent and spheroid cells, Western-blot ana-
lysis was performed. Both 5 μl and 10 μl lysate were
loaded and reacted with anti-ERBB2 antibody (Ascend
Biotechnology, AR0071) and anti-β-actin antibody
(Santa Cruz Technology).
Flow cytometric (FCM) analysis
The expression of α-gal epitopes was evaluated on
SKOV3-gal cells by flow cytometry. Approximately
1 × 106 parental SKOV3 and α1,3GT transfected cells
were suspended in 2 % BSA/PBS and incubated with
biotinylated bandeiraea simplicifolia isolectin B4 (BS-
IB4) lectins, which specifically binds to α-gal epitopes.
Then cells were incubated with PE-Cy5 conjugated
streptavidin.
The effect of cancer cell vaccine on the immune sys-
tem of the KO mice was evaluated by analyzing the
changes of CD3 + CD4+ and CD3 + CD8+ T cells in
spleen. First the spleen was removed, then cut into
pieces and grinded gently through a 200 mesh sterile
nylon net. The cell suspension was carefully collected
and layered on the Ficoll-Paque, PREMIUM (GE Health-
care Life Sciences, USA). The separated splenic
mononuclear cells were incubated with fluorochrome-
conjugated antibodies directed at the following CD
markers: PE anti-mouse CD3, FITC anti-mouse CD4,
and PE-Cy7 anti-mouse CD8 (all purchased from
eBioscience, San Diego, CA). Gated CD3 positive events
were analyzed for CD8+ and CD4+ T cells. Flow cytom-
etry was performed using a FC500 flow cytometer
(Beckman Coulter, Fullerton, CA) and analyzed using
Beckman Coulter CXP software.
Mass spectrometry analysis
Proteins were identified by mass spectrometry from
bands digested from preparative gels run with 50 μg of
protein on each lane and stained with commassie blue
staining solution. Picking, destaining, digestion, extrac-
tion, and sample preparation of the bands were carried
out. The lyophilised samples were diluted with 5 %
aqueous acetonitrile (ACN) and 0.1 % formic acid
and subsequently analyzed using a Thermo Finnigan
LTQ ion trap mass spectrometer (Thermo Finnigan,
Bremen, Germany) at the core facility of Shanghai In-
stitutes for Biological Sciences, Chinese Academy of
Sciences. Database searches were done using Sequest
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(TurboSEQUEST v. 27) search engines against the
nonredundant IPI human database version 3.68.
RNA interference
To knock down the ERBB2 gene expression, two
small interference RNAs (siRNAs) targeting different
sites of human ERBB2 mRNA (Genbank accession no.
NM_004448.3) were designed and synthesized by Gene-
Pharma Co. (Shanghai, China), and a control siRNA that
could not target any human mRNA was synthesized as a
negative control (N.C. for short). Additionally, normal
SKOV3 cells served as an untreated control (Untreated
for short). The detailed information of the siRNA was
listed in Additional file 2: Table S2.
One day prior to transfection, 1 × 105 SKOV3 cells
were seeded in six-well plates and incubated at 37 °C
with 5 % CO2 overnight. The next day, cells were grown
to about 50 % confluence and the medium was changed
for 1.5 ml fresh McCoy’s 5A medium. Then the cells
were transfected with 80 nM of siRNA using Dharma-
FECT reagent (Thermo Fisher Scientific Inc. MA. USA)
according to the manufacturer’s instructions. Forty-eight
hours after transfection, total RNA was collected for
real-time PCR analysis and proteins were collected for
western blot analysis. The primers for ERBB2 were as
follows: 5’- CGCTTTTGGCACAGTCTACA-3’ (for-
ward) and 5’- TCCCGGACATGGTCTAAGAG-3’ (re-
verse). GAPDH served as an internal control for
normalization and the primers for PCR were as follows:
5’- ATGGGCAGCCGTTAGGAAAG-3’ (forward) and
5’- TGAAGGGGTCATTGATGGCA -3’ (reverse). PCR
amplification was carried out using an initial denatur-
ation at 95 °C for 2 min, followed by 40 cycles for 5 s at
95 °C and 34 s at 60 °C.
Statistical analysis
Parametric comparisons of normally distributed values
that satisfied the variance criteria were made by
unpaired Student’s t-tests. Data that did not pass the
variance test were compared with a nonparametric two-
tailed Mann–Whitney rank sum test.
Results
Generation of stable ovarian cancer cell line SKOV3
transfectant expressing α-gal epitopes
Porcine α1,3GT cDNA was sub-cloned into pCDH-
CMV-MCS-EF1-copGFP, α1,3GT recombinant plasmid
(Additional file 3: Figure S1). Then using a three plasmid
packaging system, the recombinant lentivirus vector ex-
pressing porcine α1,3GT gene was constructed and
transferred to SKOV3 cells to produce SKOV3-gal cells.
Three days after lentivirus infection, GFP signal in
SKOV3-gal cells could be observed (Fig. 1a). High ex-
pression levels of α1,3GT mRNA were also detected in
SKOV3-gal cells by real-time PCR (p < 0.01, Fig. 1b), and
flow cytometry assay demonstrated that more than 99 %
of SKOV3 transfectant expressed α-gal epitopes on the
cell surface while only about 0.8 % of parental SKOV3
cells showed nonspecific fluorescence (Fig. 1c and d).
α-gal epitope expression did not affect the properties of
SKOV3-gal cells
Previously we reported that ovarian cancer stem-like
cells could be enriched by spheroid cell subpopulation
under stem cell selection medium [17–19]. Consistent
with it, GFP expressing SKOV3-gal cells could be
maintained and form non-adherent spheres 7 days
after culture with stem cell selection medium (Fig. 2a).
The stem cell gene expression level of NANOG and
OCT4 increased significantly in both SKOV3 spheroid
cells and SKOV3-gal spheroid cells compared with
corresponding adherent cells (Fig. 2b). Furthermore,
SKOV3-gal spheroid cells expressed significantly
higher level of α (1,3) GT (Fig. 2c, **p < 0.01), and
no significant difference was found in transcript
levels of OCT4 and NANOG compared with SKOV3
spheroid cells.
Both the adherent cells and spheroids of SKOV3-gal
cells were the same as the parental SKOV3 cells, by as-
sessment of cell morphology (Figs. 1a and 2a). To inves-
tigate whether α1,3GT transfectants could affect the
growth of ovarian cancer cells, MTT assays was per-
formed. The results demonstrated that SKOV3-gal cells
had the same proliferative capacity as their parental
SKOV3 cells (P > 0.05, Fig. 2d). In addition, a chemo-
therapy sensitivity assay was conducted and the results
suggested that there was no significant difference of
chemotherapy sensitivity to cisplatin between SKOV3
cells and SKOV3-gal cells (Fig. 2e).
Effectiveness of α-gal epitopes in inducing ovarian cancer
cells death by ADCC in vitro
There is a large amount of anti-Gal which constitutes
as much as 1 % of circulating immunoglobulin G in
humans [14]. To test the effect of human serum on
SKOV3 cells expressing gal epitope, SKOV3-gal cells
were incubated in the presence of human serum from
EOC patients and cell death was detected by MTT
assay. Parental SKOV3 cells were used as negative
controls. As shown in Fig. 3a, both SKOV3 cells and
SKOV3-gal cells were not killed by serum from EOC
patients and there was no significant difference in cell
death between SKOV3-gal cells and SKOV3 cells. In-
triguingly, however, the addition of both serum and
PBMC induced significant cell death of SKOV3-gal
cells compared with the parental SKOV3 cells, an ef-
fect that could not be reproduced by PBMC alone
(Fig. 3b).
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Vaccination with gal expression SKOV3 cells elicited the
production of anti-Gal antibodies in vivo
To identify the genotype of α1,3GT KO mice, DNA was
extracted from the tail of the α1,3GT KO and analyzed
by PCR. As shown in Fig. 4a, a 255 bp product was de-
tected in wild-type mice, whereas a 364 bp product was
produced in α1,3GT KO mice, which were similar to the
results of a previous study [23].
The anti-Gal antibody, as a natural Ab, was negative in
non-immunized α1,3GT KO mice. To generate an im-
mune response, the mice were pre-immunized four times
with 100 mg of pig kidney homogenates and then immu-
nized subcutaneously three times with SKOV3 cells,
SKOV3 spheroid cells, SKOV3-gal cells, or SKOV3-gal
spheroid cells. This elicited production of anti-Gal in the
immunized mice, quantified by ELISA using synthetic α-
gal epitopes coupled to BSA as solid-phase antigen. As
shown in Fig. 4b, KO mice immunized with SKOV3-gal
cells and SKOV3-gal spheroid cells resulted in extensive
production of anti-Gal IgG in the serum, which was
higher than that of SKOV3 cell- and SKOV3 spheroid
cell-immunized mice serum especially at the serum dilu-
tion of 1:3200 and 1:6400 (Fig. 4b, *p < 0.05). In addition,
we detected the content of the anti-alpha-gal antibodies in
serum of mice immunized with only pig kidney homoge-
nates at the serum dilution of 1:3200 and 1:6400. The re-
sults showed that mice that were pre-immunized with
pig kidney homogenates, but which were not immu-
nized with SKOV3 nor SKOV3-gal cells, induced the
production of anti-alpha-gal antibodies similar to that
of SKOV3 cell- or SKOV3 spheroid cell-immunized
mice, but lower than that of SKOV3-gal cell- or
SKOV3-gal spheroid cell-immunized mice (Additional
file 4: Figure S2.).
Fig. 1 Generation of stable α-gal epitope-expressing SKOV3 cell lines. a Following α1,3GT expressing lentivirus infection, GFP was observed on
almost all the SKOV3-gal cells under fluorescent microscopy. No GFP expression was observed on the parental SKOV3 cells. Scale bars: 200 μm.
b The expression of α1,3GT mRNA increased more than 250 times in SKOV3-gal cells compared with parental SKOV3 cells (**P < 0.01). c Only
about 0.8 % of parental SKOV3 cells showed nonspecific fluorescence. d More than 99 % of SKOV3 transfectant expressed α-gal epitopes on the
cell surface by flow cytometry
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Fig. 2 SKOV3-gal spheroid cells could be enriched and the expression of α-gal epitopes did not affect the expression of stem cell markers, cell
growth rate, and chemotherapeutic sensitivity. a Spheroid cells were formed after 7 days culture with stem cell selection medium. High GFP
expression was observed in SKOV3-gal spheroid cells, whereas there was no GFP expression in parental SKOV3 spheroid cells. b The expression
level of stem cell marker genes OCT4 and NANOG increased significantly in spheroid cells irrespective of α-gal epitope expression (*P < 0.05).
c SKOV3-gal spheroid cells expressed high levels of a1,3GT (**P < 0.01), but no significant difference was found in transcript levels of OCT4 and
NANOG compared with SKOV3 spheroid cells without gal expression. d Gal epitope expression did not affect the cell growth rate of SKOV3 cells
by MTT assay. e SKOV3 cells and SKOV3-gal cells were treated with cisplatin and survival rate of cells was determined by MTT assays. The data
were expressed as average absorbance values from five biological replicates and represent means ± standard error (P > 0.05)
Fig. 3 SKOV3-gal cells were killed by human peripheral blood mononuclear lymphocytes (PBMC) from ovarian epithelial cancer patients via
antibody dependent cell mediated cytotoxicity (ADCC). a The relative cell growth of both SKOV3 cells and SKOV3-gal cells were assayed after
culturing with different dilutions of serum supplying anti-gal Abs from ovarian epithelial cancer patients for 24 h. Data represent means ± standard
error, P > 0.05. b The cytotoxicity of PBMC and serum to both SKOV3-gal cells and SKOV3 cells was detected by MTT assays. Data represent
means ± standard error, *P < 0.05, **P < 0.01
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The inhibition of tumor growth in mice immunized with
α-gal epitope expressing cells
To observe the efficiency of the immunization of α-gal epi-
tope expressing cells, the SKOV3 tumors were grafted
under renal capsules of KO mice immunized with SKOV3-
gal cells. In 150 cases of tumor tissue implantation, 136
cases of grafted tumor continued to grow under renal cap-
sules of KO mice. Representative H&E-stained tumor tissue
showed that there was no difference between the histopath-
ology of pre-graft and post-graft tumor tissues, which were
categorized as serous adenocarcinoma of Grade 3 and was
the original tumor phenotype of the SKOV3 cell line
(Fig. 5a). Further, as shown in Fig. 5b, the tumors in non-
immunized mice kept growing post graft and increased sig-
nificantly on days 12 when compared with tumors on days
4 and days 8 (P < 0.05). However, although tumors in mice
treated with α-gal epitopes expressing SKOV3 cells seemed
to keep growing by 8 days post graft, they displayed a
slower growth rate than most SKOV3 cell- and SKOV3
spheroid cell-immunized mice. Meanwhile, by 12 days post
grafting, the mean tumor diameter decreased in all the
immunized mice. Intriguingly, mice immunized with
SKOV3-gal cells and SKOV3-gal spheroid cells induced a
reduction in tumor size compared with parental SKOV3
cell- or SKOV3 spheroid cell-immunized mice and non-
immunized mice (p < 0.05).
α-gal epitope expression induces Abs production against
special tumor antigens
To understand the induced Ab response for tumor asso-
ciated antigens (TAAs), the presence of immunostained
proteins of SKOV3 cells and SKOV3 spheroid cells was
investigated by western blot with immunized α1,3GT
KO mice serum. As shown in Fig. 6, sera from non-
immunized KO mice did not contain any Abs that
bound to SKOV3 and SKOV3 spheroid cell protein.
When reacted with protein from SKOV3 cells, sera ob-
tained from KO mice vaccinated with SKOV3-gal cells
displayed several obvious bands (including bands about
170 kDa,150 kDa, 130 kDa,70 kDa, and 55 kDa) which
were not reflected in sera obtained from SKOV3 cell-
vaccinated mice. Besides, compared with sera obtained
from SKOV3 cell-vaccinated mice, the protein bands at
50 kDa,60 kDa, and 100 kDa were thicker when the
SKOV3 cell proteins reacted with sera from KO mice
vaccinated with SKOV3-gal cells. A similar result was
also found comparing sera obtained from KO mice vac-
cinated with SKOV3-gal spheroid cells and SKOV3
spheroid cells. Sera obtained from KO mice vaccinated
with SKOV3-gal spheroid cells also displayed several ob-
vious bands (including bands about 150 kDa and
130 kDa) which were not reflected in sera obtained from
SKOV3 cell-vaccinated mice. In addition, bands about
100 kDa and 50 kDa were thicker when SKOV3 proteins
were reacted with sera obtained from SKOV3-gal spher-
oid cell-immunized mice.
However, sera obtained from KO mice vaccinated with
SKOV3 cells and SKOV3-gal cells had no significant dif-
ference of Ab bound-protein of SKOV3 spheroid cells.
Nevertheless, sera obtained from SKOV3-gal spheroid
cell-vaccinated KO mice still contained some emerging
Abs that bound to proteins (proteins about 150 kDa,
Fig. 4 Confirmation of the genotypes of the α1,3GT KO mice and anti-Gal production after immunization. a Identification of the genotype of
α1,3GT KO mice by PCR. A 255 bp product was detected in wild-type mice, whereas a 364 bp product was produced in α1,3GT KO mice. Lane 1:
DL2,000 DNA marker; lane2:genomic DNA from Wild-type mice as template; lanes 3–8:genomic DNA from six donated α1,3GT KO mice as
template; b Anti-Gal IgG production in α1,3GT KO mice pre-immunized with pig kidney membranes and then immunized with SKOV3 cells, SKOV3
spheroid cells, SKOV3-gal cells, or SKOV3-gal spheroid cells. The anti-Gal IgG production in non-immunized α1,3GT KO mice served as control
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130 kDa, and 50 kDa) which were not reflected in sera
obtained from α1,3GT KO mice vaccinated with SKOV3
spheroid cells. The different immune responses induced
by sera obtained from KO mice immunized with spher-
oid cells and parental adherent cells may result from the
different gene expression profile of SKOV3 cells and
SKOV3 spheroid cells (Additional file 5: Figure S3).
To further elucidate which proteins were contained in
the new bands, mass spectrometry was performed. The
band at 150 kDa never disappeared no matter whether
reacting with protein from SKOV3 cells or SKOV3
spheroid cells, which suggested that immunization with
SKOV3-gal spheroid cells could induce Ab production
against TAAs from both SKOV3 cells and SKOV3
spheroid cells. So the band about 150 kDa was ana-
lyzed. A protein named receptor tyrosine-protein
kinase erbB-2 (proto-oncogene c-erbB-2), which was
suggested as a prognostic factor in patients with epi-
thelial ovarian carcinoma [27–29], was found abun-
dant in the band.
siRNAs down-regulated ERBB2 mRNA expression in
SKOV3 cells and protein c-erbB-2 expression at the
150 kDa band
As shown in Fig 7a, anti-ERBB2 antibody could de-
tect two distinct bands in both adherent and spheroid
cell lysates of SKOV3 cells. And the abundance of the
bands was much higher in spheroid cells than in ad-
herent cells. The molecular weight of one band was
about 185 kDa, which should be the full length
ERBB2. The molecular weight of the other band was
between 180 kDa and 140 kDa, which was speculated
by us to be a truncated form of ERBB2 protein of
about 150 kDa. RNA interference (RNAi) technology
using small interference RNA (siRNA) was used to
knockdown ERBB2 mRNA and protein expression.
The real-time PCR analysis results showed that the
relative level of ERBB2 mRNA in SKOV3 cells trans-
fected with either siRNA-1 or siRNA-2 was signifi-
cantly lower than negative controls at 48 h after
transfection (Fig. 7b). To confirm the interference ef-
fect of siRNAs on protein expression of c-erbB-2 and
to testify whether c-erbB-2 was the main protein in
the 150 kDa band, protein collected from SKOV3
cells transfected with siRNA-1, siRNA-2, or negative
control sequence were reacted with serum from
SKOV3-gal spheroid cell-immunized mice. As shown
in Fig.7b, the 150 kDa band protein expression was
decreased after transfection with either siRNA-1 or
siRNA-2 (Fig. 7c). This result suggested that the trun-
cated c-erbB-2 (full-length c-erbB-2 was 185 kDa)
may exist in the 150 kDa band. And the mice immu-
nized with SKOV3-gal spheroid cells could produce
Abs against truncated c-erbB-2.
Fig. 5 The change of grafted tumor size in α1,3GT KO mice after tumor transplantation. a The representative histopathology of pre-graft and
post-graft tumor tissues on days 12 by H&E staining. b The SKOV3 cells that formed tumors by s.c. transplantation in athymic nude mice were
grafted under the kidney capsule of α1,3GT KO mice (n = 15 in each group). On days 4, 8, and 12, five mice in each group were sacrificed and the
diameters of the tumors were measured in situ
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Vaccination with SKOV3-gal spheroid cells promoted the
production of CD3 + CD4+ T cells in vivo
In order to determine whether gal epitope expression on
vaccinated cells could activate CD8+ T cells, which be-
come Cytotoxic T cells and destroy tumor cells, or acti-
vated CD4+ T cells, which help tumor-specific B cells to
produce antitumor antibodies [30], we performed flow
cytometry analysis. As shown in Fig. 8, compared with
their non-immunized counterparts, mice immunized
with SKOV3-gal spheroid cells demonstrated an in-
creased frequency of CD3 + CD4+ T-cells (P < 0.05), with
a concomitant decreased frequency of CD3 + CD8+ T
cells (P < 0.01). In addition, the mononuclear cells from
the spleen of SKOV3-gal spheroid vaccinated mice
displayed a significant increase in the ratio of CD3 +
CD4+ CD8- to CD3 + CD4- CD8+ compared with non-
immunized mice.
Discussion
Tumor escape from immune response is considered as
the greatest impediment to the application of effective
immunotherapy [31]. It was reported that a three-stage
process was needed for the generation of effector T cells
after vaccination with tumor cell vaccine. Firstly, an ef-
fective immune response requires tumor-antigen uptake
and processing at the site of injection by APCs. Then
APCs migrate into the regional draining lymph nodes,
where tumor-specific T cells are activated respectively by
TAA peptides presented on MHC class I and class II
molecules of APCs. Finally circulation of activated T
cells leads to tumor cell destruction [32, 33].
Since the identity of specific TAAs of most types of
cancer is not known, the irradiated autologous tumor
may be used as a source of vaccinating material.
However, tumor cells in cancer patients evolve in a
stealthy way lacking identifying markers that label
them for uptake by APC, so they can’t be detected by
APCs, even in the form of vaccine [34]. It was re-
ported that autologous tumor cell membrane vaccine
processed to express α-gal epitopes by incubating
ovarian carcinoma membranes prepared from homog-
enates of freshly obtained tumors with recombinant
α1,3GT could successfully induce anti-tumor vaccin-
ation via the formation of immune complexes by
exploiting the natural anti-Gal Ab and its ligand the
α-gal epitope [34]. However, it did not seem that all
the TAAs were on the membranes of the cancer cells
- some were within the cytoplasm of the cancer cells.
Therefore, cytoplasmic TAAs may not be targeted to
APC when the autologous tumor vaccine consists of
only tumor membranes [35]. In addition, CSCs oc-
cupy only a small size in the whole tumor population,
thus the quantity of ovarian CSCs in the tumor mem-
branes may be too small to induce immune responses
against CSCs, which might affect the efficiency of the
vaccination [36].
Previous studies showed that ovarian cancer stem-like
cells could be enriched by culturing spheroid cells under
a serum free stem cell selective system [17–19]. In the
present study, we compared SKOV3 spheroid cells and
SKOV3 differentiated cells by cDNA microarray and
found that SKOV3 spheroid cells have a distinct gene
expression profile (Additional file 5: Figure S3). By using
this cell model, we obtained intact ovarian cancer stem-
like cells expressing α-gal epitopes.
Fig. 6 Western blot staining of proteins of SKOV3 cells and SKOV3
spheroid cells with serum from immunized a1,3GT KO mice. MW,
molecular weight. Representative data of five experiments with
similar results. Lane 1: proteins incubated with serum obtained from
non-immunized mice; Lane 2: proteins incubated with serum obtained
from SKOV3 cell-immunized mice; Lane 3: proteins incubated with
serum obtained from SKOV3-gal cell-immunized mice; Lane 4: proteins
incubated with serum obtained from SKOV3 spheroid cell-immunized
mice; Lane 5: proteins incubated with serum obtained from SKOV3-gal
spheroid cell-immunized mice
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Complement dependent cytolysis (CDC) and ADCC
were suggested as the main mechanism that induce xeno-
graft cell destruction and xenograft rejection following the
binding of the natural anti-Gal to α-gal epitopes on xeno-
graft cells [37, 38]. More than 90 % of A375 melanoma
cell expression of α-gal epitopes was killed when exposed
to human serum [39]. Similarly, it was reported that 98 %
of α-gal-positive MC38 colon carcinoma cells were killed
by media containing human serum [16]. However, Li et al.
reported that there is no significant difference in suscepti-
bility to lysis at various concentrations of human serum in
three tested human tumor cell lines expressing gal epitope
compared with their corresponding parental cells [40].
Consistent with this report, we incubated SKOV3-gal cells
with different dilutions of serum obtained from ovarian
cancer patients. However, no significant difference was
found with regards to sensitivity to human serum-
mediated lysis compared with SKOV3 parental cells. It
was suggested that the complement regulatory proteins
expressed on the tumor cell surface may inhibit CDC [41].
We investigated whether SKOV3-gal cells could be killed
by ADCC. To this end, PBMC and serum from ovarian
cancer patients were separated and then co-cultured with
SKOV3-gal cells. The MTT assay showed that SKOV3-gal
cells were killed when culturing with both PBMC and
serum, implying that anti-Gal antibody in ovarian cancer
patients’ serum can bind with SKOV3-gal cells and induce
targeting of tumor cells to APCs.
The efficiency of the SKOV3-gal spheroid cell vaccine
was tested in α1,3GT KO mice. Sera obtained from mice
vaccinated with SKOV3-gal spheroid cells contained
some new Abs that reacted with protein from both
SKOV3 cells and SKOV3 spheroid cells. Mass spectro-
metric analysis demonstrated that the protein reacted
with the new Abs including a protein c-erbB-2, which
was associated with poor prognosis in cancers such as
salivary gland adenocarcinoma, breast cancer, and lung
cancer [42–44]. Meanwhile, overexpression of c-erbB-2
Fig. 7 The antibody against protein c-erbB2 could be induced by SKOV3-gal spheroid cell immunization. a Western-blot analysis of the lysates of
SKOV3 adherent and spheroid cells. 5 μl and 10 μl lysates were loaded and detected with anti-ERBB2 antibody and anti-β-actin antibody. b Real-
time PCR analysis of ERBB2 mRNA expression 48 h after transfected with siRNAs to knock down ERBB2. c Proteins of SKOV3 cells transfected with
siRNAs were collected and analyzed for protein expression at 150 kDa after incubation with serum from SKOV3-gal spheroid immunized mice by
western blot analysis. A control siRNA that could not target any human mRNA was synthesized as a negative control (N.C. for short). Additionally,
SKOV3 cells without transfectants served as untreated control (Untreated for short)
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proteins corresponded with aggressive characteristics of
tumors, such as advanced clinical stage, high grade,
presence of vascular invasion, and chemotherapy resist-
ance, suggesting potential as a prognostic marker in pa-
tients with epithelial ovarian carcinoma [27–29]. In this
study, we found c-erbB-2 proteins at the 150 kDa band
by mass spectrometry analysis. Further, the 150 kDa was
thinner when the SKOV3 cell protein was collected after
SKOV3 cells were transfected with siRNAs to knock down
ERBB2 and then incubated with serum from SKOV3-gal
spheroid cell-immunized mice. It was reported that the
expression of the NH2 terminally truncated ErbB2
(95 kDa) in breast cancer correlated with metastatic
disease progression compared with the expression of full-
length ErbB2 (185 kDa) [45]. So c-erbB2 may also be trun-
cated (about 150 kDa) in ovarian cancer and correlate
with metastatic disease progression. Future studies are re-
quired to identify and characterize this molecule as novel
TAA for immunotherapy of ovarian cancer.
It was determined that vaccination with inactivated influ-
enza virus processed by the use of recombinant 1,3GT to
express multiple α-gal epitopes could activate 12 to 13.7 %
of CD4+ T-cell, whereas no significant activation was in-
duced by virus lacking α-gal epitopes. Meanwhile, about six
Fig. 8 Flow cytometry analysis of levels of CD3 + CD4+ and CD3 + CD8+ T cells in immunized a1,3GT KO mice. Mouse spleen mononuclear cells
were isolated by density gradient centrifugation on Ficoll-Paque. And three different colors were used for CD3+, CD4+ and CD8+ membrane markers.
Gated CD3 positive events were analyzed for CD4 and CD8 production. The graph of flow cytometry represents data of five experiments with similar
results. a The distribution of CD3+CD4+ and CD3+CD8+ T cells in spleen from nonimmunized mice. b The distribution of CD3+CD4+ and CD3+CD8+
T cells in spleen from mice immunized with SKOV3 cells. c The distribution of CD3+CD4+ and CD3+CD8+ T cells in spleen from mice immunized with
SKOV3 spheroid cells. d The distribution of CD3+CD4+ and CD3+CD8+ T cells in spleen from mice immunized with SKOV3-gal cells. e The distribution
of CD3+CD4+ and CD3+CD8+ T cells in spleen from mice immunized with SKOV3-gal spheroid cells. f The frequency of CD3+CD4+ T-cells. g The
frequency of CD3+CD8+ T cells. h The ratio of CD3+CD4+ CD8- cells to CD3+CD4- CD8+ cells (*P < 0.05, **P < 0.01)
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fold higher CD8+ T-cell responses were elicited by vaccine
expression α-gal epitopes [46]. Herein, we isolated spleen
lymphocytes to identify the immune status of the immu-
nized mice, and results showed that spleen lymphocytes
from mice immunized with SKOV3-gal spheroid cells had
a higher proportion of CD3 +CD4+ T cells, while the pro-
portion of CD3 +CD8+ Tcells decreased significantly when
compared with non-immunized KO mice. Indeed, MHC
class I restricted CD8+ T cells that specifically lyse tumor
cells in vitro are frequently measured to document vaccine
efficacy and to serve as a surrogate end point in clinical
tumor vaccine trials [12, 47, 48]. However, vaccine strat-
egies that directly enhance the priming of tumor-specific
CD4+ T-cells have been shown to augment the systemic re-
jection of MHC class II negative tumors [49, 50]. Recently,
a study reported that cancer cells pre-treated with paclitaxel
and doxorubicin could enhance cancer-specific CD4+ Tcell
production and thus induce significant apoptosis and a
therapeutic anti-tumor immune response in a mouse model
[51]. In this study, CD4+ T cells also mediated significant
anti-tumor effector functions in this ovarian CSC vaccin-
ation. It seemed that mice immunized with SKOV3-gal
cells did not induce a similar immune response as SKOV3-
gal spheroid cells did, which may result from the distinct
gene expression profile of spheroid cells and adherent cells.
Unfortunately, we failed to establish an ovarian cancer
xenograft in the α1,3GT KO mice. 5 × 106 SKOV3 cells,
which formed tumors in nude mice, were injected sub-
cutaneously into α1,3GT KO female mice, however, no
macroscopic tumor developed. It was reported that hu-
man tumor xenografts, including tumors that had been
established in serial transplantation in athymic nude
mouse hosts or primary surgical tumor tissues, implanted
under the renal capsule of normal mice were quantifiable
in ocular micrometer units for six days and could retain
morphological and functional characteristics of the parent
tumors [26, 52]. So we administered injections of SKOV3
cells s.c. into female nude mice to from tumors and then
cut them into small pieces (1 mm3) to graft under the
renal capsules of immunized α1,3GT KO mice. Our re-
sults showed that the grafted tumors in non-immunized
mice continued to grow, while grafted tumors in mice im-
munized with all four kinds of vaccine (SKOV3 cells,
SKOV3 spheroid cells, SKOV3-gal cells or SKOV3-gal
spheroid cells) grew slower than non-immunized mice.
Furthermore, xenografts in mice immunized with α-gal
expressing cells were smaller at 12 days after grafting
when compared with grafts in SKOV3 cell- and SKOV3
spheroid cell-immunized mice.
Whalen and his colleagues [53] had suggested that intra-
tumoral injection of α-gal glycolipids is feasible and safe for
inducing a protective anti-tumor immune response. It was
found to be safe after intra-tumoral injection of 0.1, 1, and
10 mg α-gal glycolipids per tumor. No patients developed
clinical signs of toxicity, or any indication of autoimmunity
[53]. Accordingly, immunotherapy by synthesis of alpha-gal
epitopes on the tumor cells may be safe also, but still needs
further study.
Conclusions
Taken together, buildup of α-gal epitopes on ovarian can-
cer stem-like cells could activate effective immune re-
sponses against TAAs associated with poor prognosis of
ovarian cancer and inhibit tumor growth in vivo.
Furthermore, approaches using vaccines of α-gal epitope–
expressing ovarian cancer stem-like cells are anticipated
to induce immune responses against not only differenti-
ated cancer cells but also cancer stem-like cells, and may
lead to a cure for ovarian cancer.
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